Related Experiment Video
Updated: Sep 19, 2025

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Progression of tuberculosis among patients with rheumatic diseases - A systematic review and meta-analysis
Karthikeyan Sundaram1, Leela Kagithakara Vajravelu1, Ravichandiran Velayutham2
1Department of Microbiology, SRM Medical College Hospital and Research Centre, Kattangulathur, Chennai, 603203, Tamilnadu, India.
Background:
Tuberculosis is a contagious disease that ranks among the top ten killers of humans worldwide. Mycobacterium tuberculosis is an etiological agent of tuberculosis. The prognosis of tuberculosis in patients with autoimmune diseases is high due to treatment with anti-TNF-alpha therapy.
Methods And Materials:
We analyzed the studies based on the Preferred Reporting Items and Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Methods of eligibility criteria, search criteria and critical analyses, biased and challenges, and intervention.
Results:
We observed the tuberculosis incidence of 595 (3.25%; 95% CI- 2.9 - 3.5) cases in systemic lupus erythematosus, 332 (4.54%; 95% CI - 4.07 - 5.01) in rheumatoid arthritis, and 25 (1.9%; 95% CI - 1.16 - 2.64) in multiple sclerosis out of 26,870 study populations in the various studies, and a total of 93 (7.2%; 95% CI - 5.8 - 8.6) cases in MS, and 10 (0.05%; 95% CI - 0.02 - 0.08) in SLE reported of TB indeterminate results.
Conclusion:
This systematic review comprehensively analyzed the recent studies of the disease progression of latent tuberculosis infection to active tuberculosis is high in treatments with glucocorticoid, azathioprine, prednisone, and leflunomide among patients with autoimmune diseases.
Key Findings:
We summarized recent studies emphasizing the risk factors of tuberculosis to be found the disease-modifying anti-rheumatic drug (DMARD), immunosuppressive treatments given to biologic-naive patients as the dominant factor associated with the risk of TB and treatment with a tumor necrosis factor inhibitor.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Rheumatic Heart Disease III: Medical Management

